Cargando…
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast cancer. Twelve patients progressing after treatment with tamoxifen were randomised to...
Autores principales: | Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P. O., Lønning, P. E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075919/ https://www.ncbi.nlm.nih.gov/pubmed/8883419 |
Ejemplares similares
-
Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001) -
Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer
por: Miller, W R, et al.
Publicado: (2002) -
Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996) -
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.
por: Lønning, P. E., et al.
Publicado: (1991) -
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
por: MacNeill, F. A., et al.
Publicado: (1992)